Degrading the key component of the inflammasome: development of an NLRP3 PROTAC.

Chem Commun (Camb)

Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.

Published: January 2025

This study explores PROTACs for NLRP3, the key player in innate immunity. We utilised a thiophene analogue of the NLRP3 inhibitor MCC950 and employed CuAAC chemistry for the assembly of PROTACs bearing various linkers and recruiting three different E3 ligases. Compounds were evaluated in bidirectional thermal stability studies with NLRP3 and E3 ligases. IL-1β release and protein abundance of NLRP3 were assessed in cellular assays. PROTAC V2 induces a significant VHL-dependent degradation of NLRP3 and constitutes a valuable tool to decipher the intricate details of the NLRP3 inflammasome.

Download full-text PDF

Source
http://dx.doi.org/10.1039/d4cc06321jDOI Listing

Publication Analysis

Top Keywords

nlrp3
7
degrading key
4
key component
4
component inflammasome
4
inflammasome development
4
development nlrp3
4
nlrp3 protac
4
protac study
4
study explores
4
explores protacs
4

Similar Publications

Discovery of selective ROCK2 inhibitors with free radical scavenging ability for the treatment of gouty arthritis.

Mol Divers

January 2025

Key Laboratory of Structure-Based Drugs Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, PR China.

ROCK inhibitors can inhibit IL-1β and NLRP3, and their therapeutic potential for osteoarthritis and rheumatoid arthritis has been confirmed, but their impact on gouty arthritis has not been reported yet. By hybridization the structure of Edaravone, a series of ROCK inhibitors with pyrazolone scaffold were designed and synthesized. RM-04 has acceptable selective ROCK2 inhibitory activity with an IC of 4.

View Article and Find Full Text PDF

Degrading the key component of the inflammasome: development of an NLRP3 PROTAC.

Chem Commun (Camb)

January 2025

Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.

This study explores PROTACs for NLRP3, the key player in innate immunity. We utilised a thiophene analogue of the NLRP3 inhibitor MCC950 and employed CuAAC chemistry for the assembly of PROTACs bearing various linkers and recruiting three different E3 ligases. Compounds were evaluated in bidirectional thermal stability studies with NLRP3 and E3 ligases.

View Article and Find Full Text PDF

Background: Pulmonary arterial hypertension (PAH) is an incurable disease initiated by endothelial dysfunction, secondary to vascular inflammation and occlusive pulmonary arterial vascular remodeling, resulting in elevated pulmonary arterial pressure and right heart failure. Previous research has reported that dysfunction of type 2 bone morphogenetic protein receptor (BMPR2) signaling pathway in endothelium is inclined to prompt inflammation in PAH models, but the underlying mechanism of BMPR2 deficiency-mediated inflammation needs further investigation. This study was designed to investigate whether BMPR2 deficiency contributes to pulmonary arterial hypertension via the NLRP3 (NOD-like receptor family protein 3)/GSDME (gasdermin E)-mediated pyroptosis pathway.

View Article and Find Full Text PDF

Acute kidney injury (AKI) is a common serious complication of sepsis that is characterized by the rapid deterioration of kidney function. Neng-Jing-Huo (NJH) is an essential oil blend, including Gaultheria procumbens, Zingiber officinale, Bulnesia sarmientoi, Artemisia vulgaris, and Styrax benzoin oils, with antimicrobial, antioxidant, and anti-inflammatory activities. Here, we investigated the effects of NJH on oxidative stress, inflammatory response, and apoptosis in an in vitro septic AKI model and explored the underlying mechanisms.

View Article and Find Full Text PDF

Background: Polycystic Ovarian Syndrome (PCOS) is an endocrine disorder associated with increased risk of kidney and liver damage. Current treatments have shown contradictory outcomes, and their long-term use causes unwanted side effects. could serve as a complementary medicine to current PCOS treatments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!